Progress toward commercialization continues with BLA submission for Viaskin Peanut in children 4–7 planned for Q3 2026 and commercial launch preparations underway. Clinical programs advance with completed toddler safety study recruitment and new infant studies, while funding extends into Q3 2027.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.